# Woodwork reviews (2026): GLP-1 telehealth sellers | This GLP The advertised figure carries an asterisk, and the asterisk says forty-eight weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/woodwork Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Forty-eight weeks in an asterisk # Woodwork review The advertised figure carries an asterisk, and the asterisk says forty-eight weeks. ## The verdict Woodwork advertises compounded semaglutide from $127 a month, with an asterisk stating the price applies to a 48-week plan. Tirzepatide is $199 under the same condition. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $127/mo Prescription Required Compounded Yes — not FDA-approved Woodwork sells semaglutide as injections or oral tablets and tirzepatide by injection. Both advertised figures belong to a near-year commitment. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages name products and terms. The clinician is not described. The condition is disclosed and it is disclosed in an asterisk, which is the smallest place a forty-eight week commitment can be put. Nothing is hidden and nothing is prominent either. 2. ## What happens when the dose goes up? Nothing is published about dose on either line. The from wording leaves a floor as well, so two variables sit behind a figure that already requires most of a year. 3. ## What the price includes Forty-eight weeks at $127 is about $1,406 committed, and that is the only path to the advertised rate. No shorter term is published, so a reader wanting three months cannot price it. Tirzepatide at $199 across the same term is about $2,203. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The 48-week condition is disclosed - Strength: An oral option exists on semaglutide - Strength: Both molecules carry a figure - Limitation: The condition sits in an asterisk - Limitation: No shorter term is published at all - Limitation: Both figures also use from wording - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Woodwork. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit forty-eight weeks who reads asterisks. Wrong for A reader wanting a shorter term, which is not priced. ## The evidence behind what Woodwork prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Woodwork compares | Seller | Who it suits | Go | | --- | --- | --- | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | VitaStir | Readers who will price the rung they expect to reach rather than the entry one | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the asterisk say? That the price applies to the 48-week semaglutide injection plan. It is the condition on the advertised figure. Is a shorter plan available? None is published, so a reader wanting three months cannot price it from the site. What does the commitment total? About $1,406 for semaglutide across 48 weeks, or about $2,203 for tirzepatide. Is Woodwork expensive compared with other GLP-1 telehealth sellers? Woodwork publishes a starting figure of $127/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Woodwork below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).